CHINA SXT PHARMACEUTICALS IN (SXTC)
VGG2161P1403 - Common Stock
We assign a fundamental rating of 1 out of 10 to SXTC. SXTC was compared to 193 industry peers in the Pharmaceuticals industry. SXTC has a bad profitability rating. Also its financial health evaluation is rather negative. SXTC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SXTC has reported negative net income.
SXTC had a negative operating cash flow in the past year.
SXTC had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SXTC reported negative operating cash flow in multiple years.
1.2 Ratios
SXTC's Return On Assets of -13.40% is fine compared to the rest of the industry. SXTC outperforms 67.71% of its industry peers.
Looking at the Return On Equity, with a value of -22.24%, SXTC is in the better half of the industry, outperforming 70.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.4% | ||
| ROE | -22.24% | ||
| ROIC | N/A |
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SXTC (28.73%) is comparable to the rest of the industry.
SXTC's Gross Margin has declined in the last couple of years.
SXTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
2. Health
2.1 Basic Checks
SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
SXTC has more shares outstanding than it did 1 year ago.
SXTC has more shares outstanding than it did 5 years ago.
SXTC has a better debt/assets ratio than last year.
2.2 Solvency
SXTC has an Altman-Z score of -1.37. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.37, SXTC perfoms like the industry average, outperforming 45.31% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that SXTC is not too dependend on debt financing.
SXTC has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.37 |
ROIC/WACCN/A
WACC5.52%
2.3 Liquidity
A Current Ratio of 1.60 indicates that SXTC should not have too much problems paying its short term obligations.
SXTC has a worse Current ratio (1.60) than 73.96% of its industry peers.
SXTC has a Quick Ratio of 1.51. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC has a worse Quick ratio (1.51) than 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.52%, which is quite impressive.
SXTC shows a decrease in Revenue. In the last year, the revenue decreased by -2.11%.
Measured over the past years, SXTC shows a very negative growth in Revenue. The Revenue has been decreasing by -22.75% on average per year.
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.83%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%30.12%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SXTC. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SXTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHINA SXT PHARMACEUTICALS IN
NASDAQ:SXTC (11/4/2024, 8:00:00 PM)
After market: 0.488 +0.01 (+1.9%)0.4789
-0.05 (-9.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.67M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.4% | ||
| ROE | -22.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)44.52%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y-26.11%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y